Browse the evidence

People with type 2 diabetes should engage in physical activity regularly and reduce sedentary time.

Encourage patients to incorporate regular physical activity and minimize sedentary behavior.

Exercise timing may maximize glucose-lowering effects.

Consider advising patients on the timing of exercise to enhance glucose management.

A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.

Semaglutide may help reduce liver fibrosis in patients with MASH.

The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.

Semaglutide may lead to significant weight loss in patients with MASH.

In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

In the 5-mg tirzepatide group, 44% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 34 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Intensive lifestyle modification decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period.

Encouraging lifestyle changes can significantly reduce the risk of developing diabetes.

Intentional weight loss, particularly when substantial, lowers cardiovascular disease risk among people with overweight/obesity.

Weight management strategies should be emphasized in clinical practice to reduce CVD risk.

Treatment with once-weekly injectable semaglutide resulted in a mean change in body weight of -13.7% compared to -3.2% with placebo (P<0.001).

Semaglutide may be an effective treatment for weight loss in obese individuals with knee osteoarthritis.

Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).

Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.

Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).

Semaglutide may improve physical function in obese individuals with knee osteoarthritis.

Fewer antidiabetes medications were used in the bariatric surgery group compared to the medical/lifestyle management group.

Bariatric surgery may reduce the need for diabetes medications compared to lifestyle management.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

The mean weight loss after 3 months of semaglutide treatment was 6.7 kg, equivalent to 5.9%.

Practitioners can expect significant weight loss in patients treated with semaglutide over 3 months.

The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.

Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.

87.3% of patients achieved weight loss of 5% or more after 6 months.

Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.

Total ultra-processed food (UPF) intake is associated with a 46% higher risk of type 2 diabetes (T2D) when comparing extreme quintiles of intake.

Reducing UPF consumption may lower the risk of developing type 2 diabetes.

Liraglutide, 3.0 mg, leads to a mean percentage body weight reduction of -8.82% compared to -0.54% with placebo over 24 weeks.

Liraglutide can be considered as an effective adjunct therapy for weight management in patients struggling after metabolic surgery.

Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity.

Practitioners can consider semaglutide as an effective treatment option for weight loss in obese patients.

Tirzepatide has recently demonstrated that body weight reduction exceeding 20% in people with obesity is feasible.

Tirzepatide may be considered for patients seeking substantial weight loss.

Substitution of low- and no-calorie sweetened beverages (LNCSBs) for sugar-sweetened beverages (SSBs) was associated with a reduction in body weight by 1.06 kg.

Practitioners may consider recommending LNCSBs as a substitute for SSBs to aid in weight management.

Substitution of LNCSBs for SSBs was associated with a reduction in body mass index (BMI) by 0.32.

Practitioners may use LNCSBs to help reduce BMI in at-risk populations.

Nutritionally inadequate dietary intake is a leading contributor to chronic cardiometabolic diseases.

Practitioners should focus on improving dietary intake to prevent chronic diseases.

In adults with obesity, GLP-1 receptor agonists demonstrate 15% to 20% weight loss.

GLP-1 receptor agonists can be considered effective for weight management in obese adults.